D
Daniel Aletaha
Researcher at Medical University of Vienna
Publications - 398
Citations - 51111
Daniel Aletaha is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Rheumatoid arthritis & Medicine. The author has an hindex of 74, co-authored 298 publications receiving 43215 citations. Previous affiliations of Daniel Aletaha include National Institutes of Health & University of Vienna.
Papers
More filters
Journal ArticleDOI
Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE).
Daniel Aletaha,Clifton O. Bingham,George Karpouzas,Tsutomu Takeuchi,Carter Thorne,Carter Thorne,Androniki Bili,Prasheen Agarwal,Benjamin Hsu,Ravi Rao,Kurt Brown,Yoshiya Tanaka +11 more
TL;DR: The long-term extension of the SIRROUND-D and Round-T studies assessed longterm safety and efficacy of sirukumab in adults with moderate-to-severe RA refractory to conventional diseasemodifying antirheumatic drug therapy or antitumor necrosis factor agents as mentioned in this paper.
Posted ContentDOI
Increasing both specificity and sensitivity of SARS-CoV-2 antibody tests by using an adaptive orthogonal testing approach
Thomas Perkmann,Thomas Koller,Nicole Perkmann-Nagele,Maria Ozsvar-Kozma,David W Eyre,Philippa C Matthews,Abbie Bown,Nicole Stoesser,Marie-Kathrin Breyer,Robab Breyer-Kohansal,Otto C. Burghuber,Slyvia Hartl,Daniel Aletaha,Daniela Sieghart,Peter Quehenberger,Rodrig Marculescu,Patrick Mucher,Astrid Radakovics,Miriam Klausberger,Mark Duerkop,Barba Holzer,Boris M. Hartmann,Robert Strassl,Gerda Leitner,Florian Grebien,Wilhelm Gerner,Wilhelm Gerner,Reingard Grabherr,Oswald Wagner,Christoph J. Binder,Helmuth Haslacher +30 more
TL;DR: A novel orthogonal assay strategy is proposed that approaches 100% specificity while maintaining or even significantly improving the screening test's sensitivity.
Journal ArticleDOI
Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis.
Andrea Rubbert-Roth,Daniel Aletaha,Jenny Devenport,Paris Sidiropoulos,Yves Luder,Michael D Edwardes,Johannes W G Jacobs +6 more
TL;DR: RA duration had a statistically significant but clinically small effect on the outcomes of tocilizumab initiated in biologic-naïve patients with established RA.
Journal ArticleDOI
Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis
TL;DR: Baricitinib reduces structural damage progression versus PBO with background MTX and/or MTX, even in patients with MDA/HDA, showing a disease-modifying effect across all disease activity states.
Journal ArticleDOI
A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases
Kastriot Kastrati,Daniel Aletaha,Gerd R Burmester,E. Chwala,Christian Dejaco,Maxime Dougados,Iain B. McInnes,Angelo Ravelli,Naveed Sattar,Tanja Stamm,Y. Takeuchi,Michael Trauner,Désirée van der Heijde,Marieke Voshaar,Kevin L. Winthrop,Josef S Smolen,Andreas Kerschbaumer +16 more
TL;DR: IL-6 inhibition is effective for treatment of several inflammatory diseases with a safety profile that is widely comparable to other bDMARDs, except higher risks of diverticulitis and lower gastrointestinal perforations.